The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
@Office .. Hahahaha … Widows and orphans ..n yet you are here..:)
So they did the due diligence after they had name dropped???.. lol
I am going to give you the benefit of a doubt that you rushed in typing Re due diligence was done ..
Name calling is a sign of weakness in displaying intelligence.. maybe you should go and read the Sequence of events and come back .. lol
Enjoy the weekend anyway :)
In the board is now downhill. Even if it was an honest this will be difficult to explain away and the market will reflect that on Monday very negatively.
This company will need a strong positive RNS to be able to turn things around. All those empty tweet will not cut it now ‘so called potentials’
Can they secure that PSC , if they are able to I think we back in business and on track.
A board that could not do a simple due diligence on who wants to buy their company, I am sorry to say but that begs a lot of questions.
The fundamental I.e why most of us are here has not changed but lack of trust will now put question marks on them.
I personally will not rush to sell.. will wait for the dust to settle n that next RNS.
GLA n enjoy the weekend!!